Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer

Verastem Inc ((VSTM)) announced an update on their ongoing clinical study.

Verastem Inc. is conducting a Phase 3 study titled A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301). The study aims to evaluate the safety and efficacy of the combination of avutometinib and defactinib compared to standard treatments in patients with recurrent LGSOC who have previously undergone platinum-based therapy. This study is significant as it explores potential new treatment options for a challenging cancer type.

The study tests two investigational drugs, avutometinib and defactinib, both kinase inhibitors designed to block cancer cell growth. These are compared against standard treatments selected by investigators, including pegylated liposomal doxorubicin, paclitaxel, anastrozole, and letrozole.

This international study is randomized and open-label, with a crossover intervention model. It primarily seeks to assess treatment efficacy, focusing on progression-free survival, safety, overall survival, and quality of life.

The study began on March 18, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on July 1, 2025, indicating ongoing recruitment and study progress.

For investors, this study could influence Verastem’s stock performance, as positive results might enhance the company’s market position in oncology. It is crucial to monitor competitor activities and broader industry trends, as these factors also impact investor sentiment.

The study is ongoing, with further details accessible on the ClinicalTrials portal.